Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: When rare is too expensive

This article was originally published in Scrip

Executive Summary

When the European Medicines Agency (EMA) declined to approve Amsterdam Molecular Therapeutics’ (AMT’s) Glybera (alipogene tiparvovec) for the rare genetic disease lipoprotein lipase deficiency (LPDL) back in June (, 24 June 2011), the CEO of AMT was ‘convinced and confident’ of the approval of Europe’s first gene therapy within five months. At the end of this week, AMT completed the first, and easiest part of that process by filing an appeal against the EMA’s rejection and stated that they expected that the re-examination of the dossier would be completed by the end of 2011 (, 8 July 2011). Behind the backdrop of the appeal for re-examination which, history has shown does not have a high chance of success, the AMT annual report for 2010 reveals that the regulatory path for Glybera has been far from smooth.

You may also be interested in...

Stockwatch: Coronavirus Takes A Bite Out Of AstraZeneca’s Guidance, GSK and AbbVie Get Spinning

The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off? 

Stockwatch: Gilead, BMS Expose High Cost Of M&A

Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.

Stockwatch: Biosimilars And Dividends Connect Earnings At Pfizer And Roche

With Brexit and coronavirus depressing markets over the week, earnings season for life science companies shifted into a higher gear with a number of big companies reporting. In time, the effects of Brexit and 2019-nCoV are likely to subside, but the double-edge sword of biosimilar commercialization continues to rise from the full-year financial reports of Pfizer and Roche.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts